Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Hugh MacIsaac

Interventional Cardiology Utica, NY Medical Doctor

NPI 1669470852 CMS profile 301998

2211 Genesee St, Suite 200, Utica, NY 13501

Open in the dashboard

General payments

$8,266

321 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hugh MacIsaac of Utica, NY is reported in the CMS Open Payments database as having received $8,266 across 321 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 53rd percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $521 18
2024 General $1,539 59
2023 General $1,925 66
2022 General $1,623 60
2021 General $1,035 45
2020 General $577 17
2019 General $1,047 56

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hugh MacIsaac
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Hugh MacIsaac were reported at $521. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Hugh MacIsaac Interventional Cardiology median Middle half National median
2019 $1,047 $1,097 $329–$3,048 $163
2020 $577 $473 $161–$1,480 $114
2021 $1,035 $677 $233–$1,827 $132
2022 $1,623 $978 $333–$2,724 $149
2023 $1,925 $1,136 $382–$2,986 $160
2024 $1,539 $1,181 $395–$3,326 $164
2025 $521 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Edwards Lifesciences Corporation $2,856 107 payments
  2. Abiomed $1,209 26 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $625 32 payments
  4. Novartis Pharmaceuticals Corporation $489 36 payments
  5. Abbott Laboratories $446 3 payments
  6. Boston Scientific Corporation $430 5 payments
  7. Pfizer Inc. $319 15 payments
  8. Amgen Inc. $266 17 payments
  9. Alnylam Pharmaceuticals Inc. $262 3 payments
  10. Cardiovascular Systems Inc. $203 4 payments
  11. Other $1,162 73 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,266 321 payments
Products named General payments · program years 2019–2025
  1. Impella $1,209 26 payments
  2. JARDIANCE $449 24 payments
  3. Diamondback Peripheral $421 2 payments
  4. ENTRESTO $286 19 payments
  5. WATCHMAN Access System $260 3 payments
  6. Repatha $237 15 payments
  7. VYNDAQEL $201 8 payments
  8. LifeVest $196 14 payments
  9. XARELTO $178 16 payments
  10. Coronary Orbital Atherectomy System $178 3 payments
  11. Other $2,225 116 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 52 drugs

Part D claims

4,072

Median for Cardiology: 2,533

Drug cost

$702,917

Median for Cardiology: $485,213

Branded share of claims

28.6%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 268 $285,409
Xarelto Rivaroxaban Brand 91 $114,807
Entresto Sacubitril/Valsartan Brand 96 $111,848
Repatha Syringe Evolocumab Brand 33 $42,786
Repatha Sureclick Evolocumab Brand 33 $31,985
Jardiance Empagliflozin Brand 19 $23,156
Praluent Pen Alirocumab Brand 25 $17,730
Brilinta Ticagrelor Brand 26 $15,174
Metoprolol Succinate Generic 390 $6,321
Rosuvastatin Calcium Generic 323 $5,007

The 10 drugs with the highest cost, of 52 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 65 billing codes

Paid by Medicare

$214,372

Of which drugs: $1,134

Medicare patients

1,268

Average age 77

Services billed

2,342

605 women, 663 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 57%
Arthritis 49%
Diabetes 44%
Atrial fibrillation 40%
Heart failure 37%
Chronic kidney disease 37%
COPD 30%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 57 228 $1,112

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $66
$66 19 —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $39
$39 — —
ELIQUIS
  • PFIZER INC. $36
$36 268 —
Repatha
  • Amgen Inc. $24
$24 66 —
NURTEC ODT
  • PFIZER INC. $21
$21 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

321 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record